ADOPT, 2011 trial summary

A randomised clinical trial investigating the effect of apixaban versus enoxaparin in acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days

NCT00457002    N Engl J Med 2011;365:2167-77  




Studied treatment apixaban, administered orally at a dose of 2.5 mg twice daily for 30 days
Control treatment enoxaparin, administered subcutaneously at a dose of 40 mg once daily for 6 to 14 days



Patients acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days
Group sizes 3255 / 3273
DVT diagnosis
PE diagnosis



Blindness double-blind Inclusion period
Follow-up duration 30 days Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI PE 7 3251 8 3266 0,88[0,32; 2,43] VTE 60 2211 70 2284 0,89[0,62; 1,26] fatal PE 0 3255 0 3273 1,01[0,02; 50,69] proximal deep-vein thrombosis 53 2207 57 2276 0,96[0,66; 1,40] Venous thromboembolism or death 60 2211 70 2284 0,89[0,63; 1,26] DVT - 3255 - 3273 no data Symptomatic deep vein thrombosis during follow-up 5 3255 16 3273 0,34[0,13; 0,88] Symptomatic pulmonary embolism during follow-up - 3255 - 3273 no data Major bleeding during follow-up 15 3184 6 3217 Out of scale2,41[0,96; 6,03] All-cause death during follow-up - 3255 - 3273 no data Asymptomatic deep vein thrombosis during follow-up. 52 2206 48 2269 1,11[0,75; 1,65] net clinical benefit - 3255 - 3273 no data Clinically relevant bleeding - 3255 - 3273 no data0,22,01,0


Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011;365:2167-77     [PMID: 22077144]   link to pdf  



Registering number NCT00457002 (see trial on clinicaltrials.gov)
Code Name